N-isobutylGly-OMe | 19628-56-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-isobutylGly-OMe
• 英文别名: methyl 2-(isobutylamino)acetate；methyl isobutylglycinate；N-Isobutylglycin-OMe；Methyl 2-[(2-methylpropyl)amino]acetate；methyl 2-(2-methylpropylamino)acetate
• CAS: 19628-56-9
• 化学式: C₇H₁₅NO₂
• mdl: MFCD11140524
• 分子量: 145.202
• InChiKey: PHSQMNIJNHEJNJ-UHFFFAOYSA-N

物化性质

• 沸点：
  174.7±23.0 °C(Predicted)
• 密度：
  0.926±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-isobutylGly-OMe 在 盐酸 、 TEA 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.75h， 生成 H-(Gly-Pro-N-isobutylGly)3-OMe hydrochloride
  参考文献：
  名称：

  Collagen Mimetic Dendrimers

  摘要：

  The synthesis of single-chain, scaffold (TRIS)- and dendrimer-assembled collagen mimetics (both Gly-Pro-Nleu and Gly-Nleu-Pro sequences) is reported. From the CD spectra and the thermal denaturation studies it can be readily seen that mimetics prepared from the Gly-Nleu-Pro sequence form more thermally stable triple helices than the Gly-Pro-Nleu sequence. Furthermore, the 162-residue collagen mimetic dendrimers exhibit enhanced triple helical stability compared to equivalent scaffold-terminated structures by a substantial increase in the melting temperature in H2O and 2:1 EG/H2O. The concentration dependence for the melting transition was measured which determined that the stabilization effect arises from the intramolecular clustering of the triple helical arrays about the core structure. This ensemble excludes solvent from the interior portion of the array which stabilizes the triple helical bundle.

  DOI：

  10.1021/ja021203l
• 作为产物：
  描述：

  异丁胺 、 溴乙酸甲酯 在 三乙胺 作用下， 以88 %的产率得到N-isobutylGly-OMe
  参考文献：
  名称：

  无添加剂水基介质中更环保的拟肽合成

  摘要：

  为更绿色地合成序列定义的拟肽低聚物开发了高效程序。优化的链伸长过程在水基介质中以独特的N到C方向进行，包括方便的一锅两步脱保护/耦合序列，用于安装每个新的 peptoid 残基。该过程非常高效，每个中间偶联步骤后唯一需要的后处理程序是水萃取。与传统程序形成鲜明对比的是，在合成和后处理过程中，除水外，唯一使用的溶剂是 EtOH、MeOH 或 EtOAc。此外，除了反应介质中的试剂外，不需要专门的水溶性保护基团或添加剂。

  DOI：

  10.1039/d3gc00400g

文献信息

• 1,3-Dipolar Cycloaddition of Nitrones with 5-Methylenehydantoins: Synthesis and Transformation of New Spirohydantoin Derivatives
  作者：Amira Bahy、Yakdhane Kacem、Béchir Ben Hassine

  DOI：10.1080/00397910903097237

  日期：2010.4.12

  1,3-Dipolar cycloaddition of various acyclic nitrones with 5-methylenehydantoin derivatives afforded new chiral spiroadducts in good yields. All the spirohydantoins were obtained through a regio- and stereospecific pathway, and the spirocarbon atom was linked to the isoxazolidine oxygen atom. A representative example of the reduction of the spirohydantoin 8 with Zn/AcOH led to the substituted 1,3-aminoalcohol

  各种无环硝酮与 5-亚甲基乙内酰脲衍生物的 1,3-偶极环加成以良好的收率提供了新的手性螺旋管。所有螺乙内酰脲均通过区域和立体特异性途径获得，螺碳原子与异恶唑烷氧原子相连。用 Zn/AcOH 还原螺乙内酰脲 8 的代表性例子导致取代的 1,3-氨基醇乙内酰脲 20。
• Fused heterocyclic compounds
  申请人：——

  公开号：US20040082607A1

  公开（公告）日：2004-04-29

  The present invention provides a compound of the formula: wherein ring A is an optionally substituted 5 to 10-membered aromatic ring; R 1 and R 2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond and the like; and L is a divalent hydrocarbon group, and a salt thereof, except 3-(aminomethyl)-2,6,7-trimethyl-4-phenyl-1(2H)-isoquinolinone, 3-(aminomethyl)-2-methyl-4-phenyl-1(2H)-isoquinolinone, 3-(aminomethyl)-6-chloro-2-methyl-4-phenyl-1(2H)-isoquinolinone and 3-(aminomethyl)-2-isopropyl-4-phenyl-1(2H)-isoquinolinone. The compound shows a superior peptidase-inhibitory activity and is useful as an agent for the prophylaxis or treatment of diabetes and the like. 1

  本发明提供了一种化合物，其化学式如下：其中环A是一个可选择取代的5至10成员芳香环；R1和R2相同或不同，每个都是一个可选择取代的碳氢化合物基团或可选择取代的杂环基团；X是一个键等；L是一个二价碳氢基团，以及其盐，但不包括3-(氨甲基)-2,6,7-三甲基-4-苯基-1(2H)-异喹啉酮，3-(氨甲基)-2-甲基-4-苯基-1(2H)-异喹啉酮，3-(氨甲基)-6-氯-2-甲基-4-苯基-1(2H)-异喹啉酮和3-(氨甲基)-2-异丙基-4-苯基-1(2H)-异喹啉酮。该化合物表现出优越的肽酶抑制活性，并可用作糖尿病的预防或治疗剂等。
• [EN] BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES<br/>[FR] MODULATEURS DES LIAISONS BIDENTÉES DES KINASES LRRK2 ET JNK
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2014200682A1

  公开（公告）日：2014-12-18

  Both JNK and LRRK2 are associated with Parkinson's disease (PD), myocardial infarction (Ml), and other medical disorders. Here we report a reasonably selective and potent kinase inhibitors (e.g., compounds 6 and 10) that bound to both JNK and LRRK2 (a dual inhibitor). A bidentate-binding strategy that simultaneously utilized the ATP hinge binding and a unique protein surface site outside of the ATP pocket was applied to the design and identification of this kind of inhibitor. Compound 6 was a potent JNK3 and modest LRRK2 dual inhibitor with an enzyme IC50 value of 12 nM and 99 nM (LRRK2-G2019S), respectively. 6 also exhibited good cell potency, inhibited LRRK2:G2019S induced mitochondrial dysfunction in SHSY5Y cells, and was demonstrated to be reasonably selective against a panel of 116 kinases from representative kinase families.

  JNK和LRRK2都与帕金森病（PD）、心肌梗死（MI）和其他医学疾病相关联。在这里，我们报告了一种相对选择性和有效的激酶抑制剂（例如，化合物6和10），它们结合了JNK和LRRK2（双重抑制剂）。采用一种双齿结合策略，同时利用ATP铰链结合和ATP口袋外的独特蛋白表面位点，用于设计和识别这种抑制剂。化合物6是一种强效的JNK3和适度的LRRK2双重抑制剂，酶IC50值分别为12 nM和99 nM（LRRK2-G2019S）。6还表现出良好的细胞效力，在SHSY5Y细胞中抑制了LRRK2：G2019S诱导的线粒体功能障碍，并被证明对来自代表性激酶家族的116种激酶面板具有相当的选择性。
• FAP inhibitors
  申请人：EVANS David Michael

  公开号：US20100081701A1

  公开（公告）日：2010-04-01

  The present invention concerns compounds, according to general formula (I), which find utility preferably for the treatment of cancer.

  本发明涉及一般式（I）的化合物，其主要用于癌症治疗。
• BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US20160185818A1

  公开（公告）日：2016-06-30

  Both JNK and LRRK2 are associated with Parkinson's disease (PD), myocardial infarction (MI), and other medical disorders. Here we report a reasonably selective and potent kinase inhibitors (e.g., compounds 6 and 10) that bound to both JNK and LRRK2 (a dual inhibitor). A bidentate-binding strategy that simultaneously utilized the ATP hinge binding and a unique protein surface site outside of the ATP pocket was applied to the design and identification of this kind of inhibitor. Compound 6 was a potent JNK3 and modest LRRK2 dual inhibitor with an enzyme IC50 value of 12 nM and 99 nM (LRRK2-G2019S), respectively. 6 also exhibited good cell potency, inhibited LRRK2:G2019S induced mitochondrial dysfunction in SHSY5Y cells, and was demonstrated to be reasonably selective against a panel of 116 kinases from representative kinase families.

  JNK和LRRK2都与帕金森病（PD）、心肌梗死（MI）和其他医学疾病有关。在这里，我们报告了一种相对选择性和有效的激酶抑制剂（例如化合物6和10），它们结合了JNK和LRRK2（双重抑制剂）。采用一种双齿配体结合策略，同时利用ATP铰链结合和ATP口袋外的独特蛋白表面位点，设计和鉴定了这种抑制剂。化合物6是一种强效的JNK3和适度的LRRK2双重抑制剂，其酶IC50值分别为12 nM和99 nM（LRRK2-G2019S）。6还表现出良好的细胞效力，在SHSY5Y细胞中抑制了LRRK2：G2019S诱导的线粒体功能障碍，并被证明在代表性激酶家族的116个激酶面板中相对选择性较好。